EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Colchicine in Acute Heart Failure: Rationale and Design of a Randomized Double-Blind Placebo-Controlled Trial (COLICA)

Domingo Pascual-Figal iD, Julio Núñez Villota, Maria Teresa Pérez-Martínez, José Ramón González-Juanatey, Mikel Taibo-Urquía, Pau Llàcer Iborra, Javier González-Martín, Sandra Villar, Meritxel Soler, Sonia Mirabet, Alberto Aimo, Alejandro Riquelme-Pérez und 6 weitere

European Journal of Heart Failure · 2024

DOI: 10.1002/ejhf.3300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Domingo Pascual-Figal und 17 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain. Hauptthemen laut MEDLINE: Colchicine, Heart Failure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Heart failure (HF) elicits a pro-inflammatory state, which is associated with impaired clinical outcomes, but no anti-inflammatory therapies have demonstrated a clinical benefit yet. Inflammatory pathways related with the interleukin-1 axis are overactivated during episodes of acute HF. Colchicine, an anti-inflammatory drug with proven benefits in acute pericarditis and ischaemic heart disease, may target this inflammatory response. This study aims to assess the efficacy of colchicine in acute HF patients.

Methods

COLICA is a multicentre, randomized, double-blind, placebo-controlled trial enrolling 278 patients across 12 sites. Patients presenting with acute HF, clinical evidence of congestion requiring ≥40 mg of intravenous furosemide and N-terminal pro-B-type natriuretic peptide (NT-proBNP) >900 pg/ml, are eligible for participation. Patients are enrolled irrespective of left ventricular ejection fraction, HF type (new-onset or not) and setting (hospital or outpatient clinic). Patients are randomized 1:1 within the first 24 h of presentation to either placebo or colchicine, with an initial loading dose of 2 mg followed by 0.5 mg every 12 h for 8 weeks (reduced dose if <70 kg, >75 years old, or glomerular filtration rate <50 ml/min/1.73 m2). The primary efficacy endpoint is the time-averaged proportional change in NT-proBNP concentrations from baseline to week 8. Key secondary and exploratory outcomes include symptoms, diuretic use, worsening HF episodes, related biomarkers of cardiac stress and inflammation, total and cardiovascular readmissions, mortality and safety events.

Conclusion

COLICA will be the first randomized trial testing the efficacy and safety of colchicine for acute HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColchicineHeart FailureAgedFemaleHumansMaleMiddle AgedAcute DiseaseAnti-Inflammatory AgentsDouble-Blind MethodNatriuretic Peptide, BrainPeptide FragmentsStroke VolumeTreatment OutcomeMulticenter Studies as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

ColchicineHeart failureInflammationRandomized controlled trial

Substanzen

Anti-Inflammatory AgentsColchicineNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Autor:innen und Institutionen

  • Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain.
  • Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • CIBER cardiovascular, Madrid, Spain.
  • Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
  • IIS-Hospital Fundación Jiménez Diaz, Madrid, Spain.

ORCID-Profile: Domingo Pascual-Figal

Zitieren

APA

Pascual-Figal, D., Núñez Villota, J., Pérez-Martínez, M. T., González-Juanatey, J. R., Taibo-Urquía, M., Llàcer Iborra, P., González-Martín, J., Villar, S., Soler, M., Mirabet, S., Aimo, A., Riquelme-Pérez, A., Anguita Sánchez, M., Martínez-Sellés, M., Sánchez, P. L., Ibáñez, B., Bayés-Genís, A., & on behalf of the COLICA Investigators (see Appendix) (2024). Colchicine in Acute Heart Failure: Rationale and Design of a Randomized Double-Blind Placebo-Controlled Trial (COLICA). European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3300

Vancouver

Pascual-Figal D, Núñez Villota J, Pérez-Martínez MT, González-Juanatey JR, Taibo-Urquía M, Llàcer Iborra P, et al. Colchicine in Acute Heart Failure: Rationale and Design of a Randomized Double-Blind Placebo-Controlled Trial (COLICA). European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3300

BibTeX
@article{PascualFigal2024,
  author = {Pascual-Figal, Domingo and Núñez Villota, Julio and Pérez-Martínez, Maria Teresa and González-Juanatey, José Ramón and Taibo-Urquía, Mikel and Llàcer Iborra, Pau and González-Martín, Javier and Villar, Sandra and Soler, Meritxel and Mirabet, Sonia and Aimo, Alberto and Riquelme-Pérez, Alejandro and Anguita Sánchez, Manuel and Martínez-Sellés, Manuel and Sánchez, Pedro L and Ibáñez, Borja and Bayés-Genís, Antoni and on behalf of the COLICA Investigators (see Appendix), on behalf of the COLICA Investigators (see Appendix)},
  title = {Colchicine in Acute Heart Failure: Rationale and Design of a Randomized Double-Blind Placebo-Controlled Trial (COLICA)},
  journal = {European Journal of Heart Failure},
  year = {2024},
  doi = {10.1002/ejhf.3300}
}
Kostenlos starten →